thumbnail

S. Karger AG

  1424-8832

  1424-8840

 

Cơ quản chủ quản:  N/A

Lĩnh vực:

Các bài báo tiêu biểu

Structure-Function Relationships of C-Type Lectin-Related Proteins
Tập 34 Số 4-5 - Trang 156-159 - 2005
Takashi Morita
The structural and functional studies of the first identified C-type lectin-like protein (CLP), blood coagulation factor IX/factor X-binding protein (IX/X-bp), have been instrumental in defining how new functionally heterodimeric CLPs are generated from monomeric carbohydrate recognition domain in C-type lectins by three-dimensional domain swapping. The crystal structures of γ-carboxyglutamic acid domains of coagulation factors X and IX have recently been clarified in structural studies of complexes between the γ-carboxyglutamic acid domain of factors X and X-bp (a venom CLP) and between the γ-carboxyglutamic acid domain of factors IX and IX-bp (a venom CLP).
The insulin resistance syndrome: implications for thrombosis and cardiovascular disease
Tập 32 Số 5-6 - Trang 269-273 - 2002
I. Juhan‐Vague, Pierre‐Emmanuel Morange, Marie‐Christine Alessi
The Prothrombinase-Induced Clotting Test: A New Technique for the Monitoring of Anticoagulants
Tập 30 Số 2 - Trang 172-174 - 2000
A. Clatzis, M. Spannagl, P. Gempeler-Messina, Hans-Jürgen Kolde, W Schramm, Sylvia Haas
Pathogenesis of the acute coronary syndromes and therapeutic implications
Tập 32 Số 5-6 - Trang 225-231 - 2002
Lina Badimón, Juan J. Badimón, Gemma Vilahur, E. Segalés, V. Llorente
Factor VIII Inhibitor-Bypassing Agents Act by Inducing Thrombin Generation and Can Be Monitored by a Thrombin Generation Assay
Tập 33 Số 1 - Trang 16-22 - 2003
P L Turecek, Katalin Váradi, B. Keil, Claude Négrier, Erik Berntorp, Jan Astermark, Jean‐Claude Bordet, Massimo Morfini, Silvia Linari, HP Schwarz
Factor VIII (FVIII)-bypassing agents have complex modes of action but all control bleeding in inhibitor patients by triggering the generation of thrombin. No routine test is available for monitoring this therapy in patients with inhibitors against FVIII. We present an assay that records FEIBA- or FVIIa-mediated changes in thrombin generation (TG) in FVIII inhibitor plasma samples. In plasma samples spiked with FEIBA TG was normalized above 0.4 U/ml, while for recombinant FVIIa (rFVIIa) more than 12.5 µg/ml were required to induce TG in the absence of tissue factor (TF). Addition of TF increased the TG potential of rFVIIa in vitro. This assay seems suitable for monitoring the pharmacokinetics of inhibitor bypassing agents during treatment and possibly for predicting responses to treatment.
Atrial Fibrillation and the Hypercoagulable State: From Basic Science to Clinical Practice
Tập 33 Số 5-6 - Trang 282-289 - 2003
Anirban Choudhury, Gregory Y.H. Lip
Elevated Clotting Factor Levels and Venous Thrombosis
Tập 33 Số 5-6 - Trang 395-400 - 2003
R M Bertina
Calibrated Automated Thrombin Generation Measurement in Clotting Plasma
Tập 33 Số 1 - Trang 4-15 - 2003
H.C. Hemker, Peter Giesen, Raed Al Dieri, Véronique Regnault, Erik De Smedt, Rob Wagenvoord, Thomas Lecompte, Anne Lienhart
Calibrated automated thrombography displays the concentration of thrombin in clotting plasma with or without platelets (platelet-rich plasma/platelet-poor plasma, PRP/PPP) in up to 48 samples by monitoring the splitting of a fluorogenic substrate and comparing it to a constant known thrombin activity in a parallel, non-clotting sample. Thus, the non-linearity of the reaction rate with thrombin concentration is compensated for, and adding an excess of substrate can be avoided. Standard conditions were established at which acceptable experimental variation accompanies sensitivity to pathological changes. The coefficients of variation of the surface under the curve (endogenous thrombin potential) are: within experiment ∼3%; intra-individual: <5% in PPP, <8% in PRP; interindividual 15% in PPP and 19% in PRP. In PPP, calibrated automated thrombography shows all clotting factor deficiencies (except factor XIII) and the effect of all anticoagulants [AVK, heparin(-likes), direct inhibitors]. In PRP, it is diminished in von Willebrand’s disease, but it also shows the effect of platelet inhibitors (e.g. aspirin and abciximab). Addition of activated protein C (APC) or thrombomodulin inhibits thrombin generation and reflects disorders of the APC system (congenital and acquired resistance, deficiencies and lupus antibodies) independent of concomitant inhibition of the procoagulant pathway as for example by anticoagulants.